- Home
- ONDS vs SLS Comparison
ONDS vs SLS Comparison
Compare ONDS & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- SLS
- Stock Information
- Founded
- ONDS 2014
- SLS 2012
- Country
- ONDS United States
- SLS United States
- Employees
- ONDS N/A
- SLS N/A
- Industry
- ONDS Telecommunications Equipment
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- ONDS Telecommunications
- SLS Health Care
- Exchange
- ONDS Nasdaq
- SLS Nasdaq
- Market Cap
- ONDS 102.0M
- SLS 89.6M
- IPO Year
- ONDS N/A
- SLS N/A
- Fundamental
- Price
- ONDS $0.87
- SLS $1.56
- Analyst Decision
- ONDS Strong Buy
- SLS
- Analyst Count
- ONDS 2
- SLS 0
- Target Price
- ONDS $3.25
- SLS N/A
- AVG Volume (30 Days)
- ONDS 5.1M
- SLS 2.2M
- Earning Date
- ONDS 05-15-2025
- SLS 05-20-2025
- Dividend Yield
- ONDS N/A
- SLS N/A
- EPS Growth
- ONDS N/A
- SLS N/A
- EPS
- ONDS N/A
- SLS N/A
- Revenue
- ONDS $7,192,694.00
- SLS N/A
- Revenue This Year
- ONDS $256.61
- SLS N/A
- Revenue Next Year
- ONDS $104.92
- SLS N/A
- P/E Ratio
- ONDS N/A
- SLS N/A
- Revenue Growth
- ONDS N/A
- SLS N/A
- 52 Week Low
- ONDS $0.54
- SLS $0.77
- 52 Week High
- ONDS $3.40
- SLS $1.85
- Technical
- Relative Strength Index (RSI)
- ONDS 52.44
- SLS 51.33
- Support Level
- ONDS $0.76
- SLS $1.36
- Resistance Level
- ONDS $0.80
- SLS $1.85
- Average True Range (ATR)
- ONDS 0.06
- SLS 0.14
- MACD
- ONDS 0.02
- SLS -0.02
- Stochastic Oscillator
- ONDS 73.13
- SLS 21.00
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.